Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.

Hsiao C. Li, Christy A. Russell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although anthracyclines and the taxanes comprise the most active first-line cytotoxic treatments in patients with hormone-insensitive or life-threatening metastatic breast cancer, many patients progress and require other chemotherapeutic agents. Development of new combinations and/or agents is thus needed. Gemcitabine (Gemzar) and platinum compounds have been employed as single agents, and the addition of gemcitabine to the platinums results in significant clinical benefit and response rates. Correlative biologic studies are expected from several already-reported trials and may help elucidate predictive factors for both response and toxicity when combining gemcitabine and the platinums. Trials incorporating these doublets in earlier stages of breast cancer or in the neoadjuvant setting may further elucidate their role in breast cancer treatment.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalOncology (Williston Park, N.Y.)
Volume18
Issue number14 Suppl 12
StatePublished - Dec 2004

Fingerprint

gemcitabine
Platinum
Breast Neoplasms
Drug Therapy
Platinum Compounds
Taxoids
Anthracyclines
Hormones
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. / Li, Hsiao C.; Russell, Christy A.

In: Oncology (Williston Park, N.Y.), Vol. 18, No. 14 Suppl 12, 12.2004, p. 17-22.

Research output: Contribution to journalArticle

@article{3328170e2e594af5878481fa967f9faf,
title = "Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.",
abstract = "Although anthracyclines and the taxanes comprise the most active first-line cytotoxic treatments in patients with hormone-insensitive or life-threatening metastatic breast cancer, many patients progress and require other chemotherapeutic agents. Development of new combinations and/or agents is thus needed. Gemcitabine (Gemzar) and platinum compounds have been employed as single agents, and the addition of gemcitabine to the platinums results in significant clinical benefit and response rates. Correlative biologic studies are expected from several already-reported trials and may help elucidate predictive factors for both response and toxicity when combining gemcitabine and the platinums. Trials incorporating these doublets in earlier stages of breast cancer or in the neoadjuvant setting may further elucidate their role in breast cancer treatment.",
author = "Li, {Hsiao C.} and Russell, {Christy A.}",
year = "2004",
month = "12",
language = "English (US)",
volume = "18",
pages = "17--22",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "14 Suppl 12",

}

TY - JOUR

T1 - Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.

AU - Li, Hsiao C.

AU - Russell, Christy A.

PY - 2004/12

Y1 - 2004/12

N2 - Although anthracyclines and the taxanes comprise the most active first-line cytotoxic treatments in patients with hormone-insensitive or life-threatening metastatic breast cancer, many patients progress and require other chemotherapeutic agents. Development of new combinations and/or agents is thus needed. Gemcitabine (Gemzar) and platinum compounds have been employed as single agents, and the addition of gemcitabine to the platinums results in significant clinical benefit and response rates. Correlative biologic studies are expected from several already-reported trials and may help elucidate predictive factors for both response and toxicity when combining gemcitabine and the platinums. Trials incorporating these doublets in earlier stages of breast cancer or in the neoadjuvant setting may further elucidate their role in breast cancer treatment.

AB - Although anthracyclines and the taxanes comprise the most active first-line cytotoxic treatments in patients with hormone-insensitive or life-threatening metastatic breast cancer, many patients progress and require other chemotherapeutic agents. Development of new combinations and/or agents is thus needed. Gemcitabine (Gemzar) and platinum compounds have been employed as single agents, and the addition of gemcitabine to the platinums results in significant clinical benefit and response rates. Correlative biologic studies are expected from several already-reported trials and may help elucidate predictive factors for both response and toxicity when combining gemcitabine and the platinums. Trials incorporating these doublets in earlier stages of breast cancer or in the neoadjuvant setting may further elucidate their role in breast cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=15544379692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15544379692&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 17

EP - 22

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 14 Suppl 12

ER -